Request Sample Form

Name*:

Phone No.*:

Email*:

Service Intersted In:

Download Complete Report

Your Name*:

Email*:

Contact Number*:

Subject*:

Service Interested In* (required)

Your Requirment*:

Orphan Drug Designation granted for AZ’ Imfinzi

AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Imfinzi (durvalumab) for the treatment of small cell lung cancer (SCLC).

July 12th, 2019|News|

US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer

Pancreatic cancer is a rare, life-threatening disease that accounts for about 3% of all cancers in the US. Due to the late onset of symptoms, patients are often diagnosed after cancer has progressed to locally advanced or metastatic stages of the disease.

October 18th, 2018|News|